文献速递类风湿关节炎

类风湿关节炎缓解期患者TNF抑制剂减量对比稳定治疗对疾病复发的影响:一项随机、开放标签、非劣效性试验

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
PubMed 文献 · Ann Rheum Dis · 2023-08-22

ARCTIC REWIND TNFi研究在挪威9个风湿科开展,纳入缓解≥12个月的类风湿关节炎患者,比较TNF抑制剂减量至停药与稳定治疗。减量组27/43(63%)复发,稳定组2/41(5%),风险差58%(95%CI 42%至74%),减量策略未达非劣效;但多数患者恢复全剂量后重新缓解。

要点

  • 减量至停药组12个月内复发27/43(63%),稳定治疗组2/41(5%)。
  • 风险差58%(95%CI 42%至74%),减量策略未达非劣效(界值20%)。
  • 多数复发患者恢复全剂量TNF抑制剂后重新达到缓解。

核心结论

  • 在TNF抑制剂治疗下缓解超过1年的类风湿关节炎患者中,减量至停药者复发率升高。
  • 多数患者在恢复全剂量治疗后重新达到缓解。

研究设计与样本

  • 随机、开放标签、非劣效性试验,在挪威9个风湿科开展。
  • 纳入缓解≥12个月且稳定使用TNF抑制剂的患者,计算机区组随机分配至减量至停药组或稳定TNF抑制剂组,传统合成改善病情抗风湿药联用不变。
  • 主要终点为12个月研究期间疾病复发,非劣效界值20%,在意向方案人群中评估。
  • 2013年6月至2019年1月共纳入99例,92例接受分配的治疗策略,84例纳入意向方案人群。

主要发现

  • 减量TNF抑制剂组27/43(63%)在12个月内复发,稳定TNF抑制剂组2/41(5%)复发,风险差58%(95%CI 42%至74%)。
  • 减量策略未达非劣效于持续稳定治疗。
  • 减量组不良事件总数/严重不良事件为49/3,稳定组为57/2。

关键数值与推荐

  • 非劣效界值为20%。
  • 主要终点在意向方案人群中评估,减量组复发27/43(63%),稳定组2/41(5%),风险差58%(95%CI 42%至74%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Many patients with rheumatoid arthritis (RA) require treatment with tumour necrosis factor inhibitor (TNFi) to reach remission. It is debated whether tapering of TNFi to discontinuation should be considered in sustained remission. The aim of ARCTIC REWIND TNFi was to assess the effect of tapering TNFi to withdrawal compared with stable treatment on the risk of disease activity flares in patients with RA in remission ≥1 year. METHODS: This randomised, open-label, non-inferiority trial was undertaken at nine Norwegian rheumatology departments. Patients with RA in remission ≥12 months on stable TNFi therapy were allocated by computer-based block-randomisation to tapering to discontinuation of TNFi or stable TNFi. Conventional synthetic disease-modifying antirheumatic co-medication was unchanged. The primary endpoint was disease flare during the 12-month study period (non-inferiority margin 20%), assessed in the per-protocol population. RESULTS: Between June 2013 and January 2019, 99 patients were enrolled and 92 received the allocated treatment strategy. Eighty-four patients were included in the per-protocol population. In the tapering TNFi group, 27/43 (63%) experienced a flare during 12 months, compared with 2/41 (5%) in the stable TNFi group; risk difference (95% CI) 58% (42% to 74%). The tapering strategy was not non-inferior to continued stable treatment. The number of total/serious adverse events was 49/3 in the tapering group, 57/2 in the stable group. CONCLUSION: In patients with RA in remission for more than 1 year while using TNFi, an increase in flare rate was reported in those who tapered TNFi to discontinuation. However, most regained remission after reinstatement of full-dose treatment. TRIAL REGISTRATION NUMBERS: EudraCT: 2012-005275-14 and clinicaltrials.gov: NCT01881308.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis. 2023. PMID: 37607809. doi:10.1136/ard-2023-224476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。